Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with...

ver descrição completa

Detalhes bibliográficos
Autores: Vigón, Lorena, Vázquez Morón, Sonia, Berenguer, Juan, González García, Juan Julián, Jiménez Sousa, María Angeles, Guardional, Josep M., Crespo, Manuel, Santos Gil, Ignacio de los, Von Wichmann, Miguel A., Carrero, Ana, Yélamos, María Belén, Gómez, Julián, Resino, Salvador, Martínez, Isidoro, The GESIDA 3603b Cohort Study Group
Formato: artículo
Fecha de publicación:2019
País:España
Recursos:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/690592
Acesso em linha:http://hdl.handle.net/10486/690592
https://dx.doi.org/10.1038/s41598-019-48592-5
Access Level:acceso abierto
Palavra-chave:HIV/HCV-coinfected patients
SVR
anti-HCV antibodies
Medicina
Descrição
Resumo:The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with pegIFNα+ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against fve JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR

Registos relacionados